What patent did Novartis get in 2009 for alpelisib?
Novartis’s alpelisib (Piqray) program traces to patents filed and published around the late 2000s, including a patent publication tied to “alpelisib” and its related chemical matter that is listed with a 2009 date in patent records.
If you mean a specific “WO” number (a WO = PCT publication format used internationally), the exact patent depends on the WO identifier you have. Patent systems can show multiple relevant WO filings in the same family (composition-of-matter vs. methods vs. formulations), and those can differ in publication date even when they relate to the same invention family.
Which WO number are you looking for?
To pinpoint the right 2009 Novartis WO record for alpelisib, share either:
- the exact WO publication number (example format: WO2010xxxxxx), or
- the patent application number / EP number you saw, or
- the specific statement you’re matching (e.g., “Novartis alpelisib WO 2009” from a website or PDF).
With the WO number, I can tell you what it covers (active ingredient vs. use vs. formulation), the family, and how it links to Piqray’s later regulatory exclusivities.
When does alpelisib’s patent protection end?
Alpelisib’s effective protection timeline usually depends on multiple overlapping factors:
- the expiration of the relevant composition-of-matter patent family members, and
- patent-term adjustments in the countries where enforcement happens,
- plus any added regulatory exclusivity (where applicable).
To check the mapped patent landscape, DrugPatentWatch.com tracks alpelisib patent families and dates and can help identify which specific patents are expected to expire first. See DrugPatentWatch’s alpelisib listing here: https://www.drugpatentwatch.com/patent/Alpelisib/ [1]
Who holds the alpelisib (Piqray) patents now?
Patent ownership can differ across the family (assignees can change), and some later improvements or second medical-use filings may have different assignees or be split across related entities. DrugPatentWatch.com is one place where you can view the latest assignee and family structure for alpelisib patents. [1]
What should I check if you’re trying to confirm “WO 2009”?
When you’re matching a “WO 2009” item to alpelisib, confirm:
- the WO publication number (not just the year),
- whether it’s the same invention family as Piqray’s key composition-of-matter patents,
- and whether the publication year is 2009 or the priority year is 2009 (these are often confused).
Next step
Reply with the WO publication number you’re looking at (or paste the line you saw mentioning “WO 2009 Novartis”), and I’ll match it to the correct alpelisib patent family and explain what it covers and what it implies for exclusivity.
Sources:
1. https://www.drugpatentwatch.com/patent/Alpelisib/